A detailed history of Rhenman & Partners Asset Management Ab transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 102,500 shares of VKTX stock, worth $5.39 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
102,500
Previous 115,000 10.87%
Holding current value
$5.39 Million
Previous $6.1 Million 6.45%
% of portfolio
0.54%
Previous 0.6%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$49.84 - $70.47 $623,000 - $880,875
-12,500 Reduced 10.87%
102,500 $6.49 Million
Q2 2024

Aug 13, 2024

SELL
$47.39 - $80.2 $1.42 Million - $2.41 Million
-30,000 Reduced 20.69%
115,000 $6.1 Million
Q1 2024

May 14, 2024

SELL
$17.4 - $94.5 $609,000 - $3.31 Million
-35,000 Reduced 19.44%
145,000 $11.9 Million
Q3 2023

Nov 13, 2023

BUY
$10.92 - $16.0 $1.27 Million - $1.86 Million
116,500 Added 183.46%
180,000 $1.99 Million
Q3 2023

Nov 09, 2023

SELL
$10.92 - $16.0 $1.27 Million - $1.86 Million
-116,500 Reduced 64.72%
63,500 $702,000
Q1 2023

May 11, 2023

BUY
$8.08 - $17.33 $1.45 Million - $3.12 Million
180,000 New
180,000 $3 Million
Q2 2020

Jul 16, 2020

SELL
$4.35 - $8.08 $869,999 - $1.62 Million
-200,000 Closed
0 $0
Q3 2019

Oct 16, 2019

SELL
$6.55 - $8.6 $599,318 - $786,891
-91,499 Reduced 31.39%
200,000 $1.38 Million
Q2 2019

Jul 22, 2019

BUY
$7.67 - $10.63 $2.24 Million - $3.1 Million
291,499 New
291,499 $2.42 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.